Latest Earnings Results: Q2 '26
Estimated EPS
-$0.06
Reported EPS
-$0.06
Surprise
+4%
Estimated Rev
$0M
Reported Rev
---
Surprise
---
Reported GAAP EPS of -$0.06 up 40.00% YoY
Bullish Takeaway
Talphera achieved 75% enrollment in its NEPHRO CRRT study, benefited from favorable draft 2026 KDIGO guidelines for nafamostat, and identified a 21% increase in projected U.S. CRRT procedures by 2027.
Bearish Takeaway
Talphera reported a wider net loss and increased operating expenses for the second quarter of 2026, while facing ongoing regulatory and clinical development risks for its lead product candidate, Niyad.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.07 | -- | -- | N/A |
Q2 '26 | -$0.06 | -$0.06 | 4.00% | BEAT |
Q1 '26 | -$0.07 | -$0.04 | 40.00% | BEAT |
Q4 '25 | -$0.08 | -$0.06 | 20.00% | BEAT |
Q3 '25 | -$0.12 | -$0.11 | 12.00% | BEAT |